A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Dec 2018 Planned End Date changed from 25 Aug 2020 to 23 Oct 2020.
- 18 Dec 2018 Planned primary completion date changed from 25 Aug 2020 to 23 Oct 2020.
- 18 Dec 2018 Planned initiation date changed from 23 Mar 2019 to 6 May 2019.